PURPOSE: We aimed to determine the natural history of small index lesions identified on multiparametric-magnetic resonance imaging (MP-MRI) of the prostate by evaluating lesion-specific pathology and growth on serial MP-MRI. MATERIALS AND METHODS: We performed a retrospective review of 153 patients who underwent a minimum of two MP-MRI sessions, on an institutional review board-approved protocol. Index lesion is defined as the lesion(s) with the highest cancer suspicion score based on initial MP-MRI of a patient, irrespective of size. Two study cohorts were identified: (1) patients with no index lesion or index lesion(s) ≤7 mm and (2) a subset with no index lesion or index lesion(s) ≤5 mm. Pathological analysis of the index lesions was performed following magnetic resonance/ultrasound fusion-guided biopsy. Growth rate of the lesions was calculated based on MP-MRI follow-up. RESULTS: Patients with small index lesions measuring ≤7 mm (n=42) or a subset with lesions ≤5 mm (n=20) demonstrated either benign findings (86.2% and 87.5%, respectively) or low grade Gleason 6 prostate cancer (13.8% and 12.5%, respectively) on lesion-specific targeted biopsies. These lesions demonstrated no significant change in size (P = 0.93 and P = 0.36) over a mean imaging period of 2.31±1.56 years and 2.40±1.77 years for ≤7 mm and ≤5 mm index lesion thresholds, respectively. These findings held true on subset analyses of patients who had a minimum of two-year interval follow-up with MP-MRI. CONCLUSION: Small index lesions of the prostate are pathologically benign lesions or occasionally low-grade cancers. Slow growth rate of these small index lesions on serial MP-MRI suggests a surveillance interval of at least two years without significant change.
PURPOSE: We aimed to determine the natural history of small index lesions identified on multiparametric-magnetic resonance imaging (MP-MRI) of the prostate by evaluating lesion-specific pathology and growth on serial MP-MRI. MATERIALS AND METHODS: We performed a retrospective review of 153 patients who underwent a minimum of two MP-MRI sessions, on an institutional review board-approved protocol. Index lesion is defined as the lesion(s) with the highest cancer suspicion score based on initial MP-MRI of a patient, irrespective of size. Two study cohorts were identified: (1) patients with no index lesion or index lesion(s) ≤7 mm and (2) a subset with no index lesion or index lesion(s) ≤5 mm. Pathological analysis of the index lesions was performed following magnetic resonance/ultrasound fusion-guided biopsy. Growth rate of the lesions was calculated based on MP-MRI follow-up. RESULTS:Patients with small index lesions measuring ≤7 mm (n=42) or a subset with lesions ≤5 mm (n=20) demonstrated either benign findings (86.2% and 87.5%, respectively) or low grade Gleason 6 prostate cancer (13.8% and 12.5%, respectively) on lesion-specific targeted biopsies. These lesions demonstrated no significant change in size (P = 0.93 and P = 0.36) over a mean imaging period of 2.31±1.56 years and 2.40±1.77 years for ≤7 mm and ≤5 mm index lesion thresholds, respectively. These findings held true on subset analyses of patients who had a minimum of two-year interval follow-up with MP-MRI. CONCLUSION: Small index lesions of the prostate are pathologically benign lesions or occasionally low-grade cancers. Slow growth rate of these small index lesions on serial MP-MRI suggests a surveillance interval of at least two years without significant change.
Authors: Tineke Wolters; Monique J Roobol; Pim J van Leeuwen; Roderick C N van den Bergh; Robert F Hoedemaeker; Geert J L H van Leenders; Fritz H Schröder; Theodorus H van der Kwast Journal: J Urol Date: 2010-11-12 Impact factor: 7.450
Authors: Baris Turkbey; Haresh Mani; Vijay Shah; Ardeshir R Rastinehad; Marcelino Bernardo; Thomas Pohida; Yuxi Pang; Dagane Daar; Compton Benjamin; Yolanda L McKinney; Hari Trivedi; Celene Chua; Gennady Bratslavsky; Joanna H Shih; W Marston Linehan; Maria J Merino; Peter L Choyke; Peter A Pinto Journal: J Urol Date: 2011-09-25 Impact factor: 7.450
Authors: Ardeshir R Rastinehad; Angelo A Baccala; Paul H Chung; Juan M Proano; Jochen Kruecker; Sheng Xu; Julia K Locklin; Baris Turkbey; Joanna Shih; Gennady Bratslavsky; W Marston Linehan; Neil D Glossop; Pingkun Yan; Samuel Kadoury; Peter L Choyke; Bradford J Wood; Peter A Pinto Journal: J Urol Date: 2011-01-15 Impact factor: 7.450
Authors: Peter A Pinto; Paul H Chung; Ardeshir R Rastinehad; Angelo A Baccala; Jochen Kruecker; Compton J Benjamin; Sheng Xu; Pingkun Yan; Samuel Kadoury; Celene Chua; Julia K Locklin; Baris Turkbey; Joanna H Shih; Stacey P Gates; Carey Buckner; Gennady Bratslavsky; W Marston Linehan; Neil D Glossop; Peter L Choyke; Bradford J Wood Journal: J Urol Date: 2011-08-17 Impact factor: 7.450
Authors: Baris Turkbey; Peter A Pinto; Haresh Mani; Marcelino Bernardo; Yuxi Pang; Yolanda L McKinney; Kiranpreet Khurana; Gregory C Ravizzini; Paul S Albert; Maria J Merino; Peter L Choyke Journal: Radiology Date: 2010-04 Impact factor: 11.105
Authors: Dima Raskolnikov; Soroush Rais-Bahrami; Arvin K George; Baris Turkbey; Nabeel A Shakir; Chinonyerem Okoro; Jason T Rothwax; Annerleim Walton-Diaz; M Minhaj Siddiqui; Daniel Su; Lambros Stamatakis; Pingkun Yan; Jochen Kruecker; Sheng Xu; Maria J Merino; Peter L Choyke; Bradford J Wood; Peter A Pinto Journal: J Urol Date: 2014-08-20 Impact factor: 7.450
Authors: Samrad Ghavimi; Hamidreza Abdi; Jennifer Waterhouse; Richard Savdie; Silvia Chang; Alison Harris; Lindsay Machan; Martin Gleave; Alan I So; Larry Goldenberg; Peter C Black Journal: Can Urol Assoc J Date: 2018-04-06 Impact factor: 1.862
Authors: R A Rakow-Penner; N S White; J K Parsons; H W Choi; M A Liss; J M Kuperman; N Schenker-Ahmed; H Bartsch; R F Mattrey; W G Bradley; A Shabaik; J Huang; D J A Margolis; S S Raman; L Marks; C J Kane; R E Reiter; D S Karow; A M Dale Journal: Prostate Cancer Prostatic Dis Date: 2015-01-06 Impact factor: 5.554
Authors: Michele Fascelli; Arvin K George; Thomas Frye; Baris Turkbey; Peter L Choyke; Peter A Pinto Journal: Curr Urol Rep Date: 2015-06 Impact factor: 3.092
Authors: Baris Turkbey; Anna M Brown; Sandeep Sankineni; Bradford J Wood; Peter A Pinto; Peter L Choyke Journal: CA Cancer J Clin Date: 2015-11-23 Impact factor: 508.702
Authors: Rebecca A Rakow-Penner; Nathan S White; Daniel J A Margolis; John Kellogg Parsons; Natalie Schenker-Ahmed; Joshua M Kuperman; Hauke Bartsch; Hyung W Choi; William G Bradley; Ahmed Shabaik; Jiaoti Huang; Michael A Liss; Leonard Marks; Christopher J Kane; Robert E Reiter; Steven S Raman; David S Karow; Anders M Dale Journal: Magn Reson Imaging Date: 2015-07-26 Impact factor: 2.546
Authors: Vidhush K Yarlagadda; Win Shun Lai; Jennifer B Gordetsky; Kristin K Porter; Jeffrey W Nix; John V Thomas; Soroush Rais-Bahrami Journal: Diagn Interv Radiol Date: 2018 May-Jun Impact factor: 2.630
Authors: Raju Chelluri; Amichai Kilchevsky; Arvin K George; Abhinav Sidana; Thomas P Frye; Daniel Su; Michele Fascelli; Richard Ho; Steven F Abboud; Baris Turkbey; Maria J Merino; Peter L Choyke; Bradford J Wood; Peter A Pinto Journal: J Urol Date: 2016-02-13 Impact factor: 7.450
Authors: Ely R Felker; Jason Wu; Shyam Natarajan; Daniel J Margolis; Steven S Raman; Jiaoti Huang; Fred Dorey; Leonard S Marks Journal: J Urol Date: 2015-12-07 Impact factor: 7.450